Global recombinant protein market is expected to reach nearly US$ 460 Mn by 2022-end

Fact.MR Fact.MR

Dublin 2, Ireland, 2018-Feb-07 — /EPR Network/ — Recombinant proteins play an imperative role in treating various diseases, such as hemophilia. Majority of the recombinant proteins used are human proteins, in order to compensate the functional proteins in vivo defects by increasing the protein function in a body. This Fact.MR report analyzes the expansion of global recombinant protein market till date, and provides key insights on the growth of the market during the forecast period, 2017-2022.

The scope of Fact.MR’s report is to analyze the global recombinant protein market for the forecast period 2017-2022 and provide readers an unbiased and accurate analysis. Medical device manufacturers, research institutes, and raw material suppliers in the global recombinant protein market can benefit from the analysis offered in this report. This report offers a comprehensive analysis, which can be of interest to leading trade magazines and medical journals pertaining to recombinant protein.

Request Free Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=186

10 Key Estimations on Future of Global Recombinant Protein Market

1.      Basic research will remain the largest application segment in the global recombinant proteins market. Revenues from basic research will reach roughly US$ 270 Mn in revenues by the end of 2022.

2.      Toxicity screening, and drug discovery & development will witness the fastest expansion through 2022, based on application of recombinant proteins.

3.      Recombinant protein sales for forensic testing application will exhibit the lowest CAGR in the market through 2022.

4.      North America is projected to remain dominant in the global market for recombinant proteins, with sales poised to account for approximately US$ 150 Mn revenues by 2022-end.

5.      Europe will continue to be the second largest market for recombinant proteins over the forecast period.

6.      The market for recombinant protein in Middle East & Africa (MEA) will exhibit a sluggish expansion through 2022.

7.      Academic & research institutes will remain the most lucrative end-users in the global recombinant proteins market, accounting for more than one-third revenue share of the market throughout the forecast period.

8.      Biopharmaceutical companies will continue to be the fastest expanding end-users of recombinant proteins in the global market.

9.      Although growth factors are estimated to remain the largest product segment, sales of chemokines will register the fastest expansion through 2022.

Browse Full Report with TOC- https://www.factmr.com/report/186/recombinant-protein-market

North America to Remain Dominant in the Market

North America will continue to retain its dominance in the global recombinant protein market, with sales projected to reach nearly US$ 150 Mn by 2022-end. Europe is estimated to be the second most lucrative market for recombinant protein throughout the forecast period. The market in Middle East & Africa (MEA) is anticipated to witness a sluggish expansion through 2022.

Recombinant proteins factoring molecular growth will remain the most lucrative product in the market, followed by checkpoint regulators. In addition, sales of growth factors, and cytokines are poised to exhibit similar CAGRs through 2022. However, sales of chemokines are estimated to register the fastest expansion through 2022. Demand for enzymes & inhibitors will continue to be sluggish throughout the forecast period.

Although academic & research institutes are expected to remain the largest end-users of recombinant proteins in terms of revenues, sales in biopharmaceutical companies will register the highest CAGR compared to all the other end-user segments through 2022. Revenues from sales of recombinant proteins in academic & research institutes will account for over one-third market share during 2017 to 2022.

Recombinant proteins will continue to find the largest application in basic research activities. Revenues from recombinant proteins for basic research are expected to account for around US$ 270 Mn by 2022-end. Drug discovery & development, and toxicity screening are estimated to emerge as the fastest growing applications of recombinant proteins. Sales of recombinant proteins for application in forensic testing are estimated to register the lowest CAGR through 2022.

Competition Tracking

Leading players in the global recombinant protein market include Abcam plc, A.M.S. Biotechnology (Europe) Limited, Bio-Rad Laboratories, Inc., BPS Bioscience Inc., PerkinElmer, Inc., Crown Bioscience, Inc., GenScript Corporation, Merck Millipore Limited, Sigma Aldrich, and Thermo Fisher Scientific, Inc.

Check Discount- https://www.factmr.com/connectus/sample?flag=D&rep_id=186

About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized  Healthcare market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Fact.MR
Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Telephone: +353-1-6111-593
Email: sales@factmr.com/
Web: https://www.factmr.com/

Matched content

Editor’s pick